Cyclophosphamide in relapsing remitting multiple sclerosis.
7 patients with relapsing-remitting multiple sclerosis (MS) were subjected to an intensive course of intravenous (I.V.) cyclophosphamide (CY) therapy. All patients received induction therapy with 11 daily doses of 300 mg/m2 and then a single dose every six months for three years. After one year of follow-up all patients showed a decrease in relapse rate (0.57.57); in the two subsequent years of follow-up 2 patients showed a mild worsening while the others were clinically stable. As suggested by others, our results indicate that I.V. CY therapy may influence the clinical course of relapsing-remitting MS.
D'Andrea
F
F
Clinica Neurologica dell'Università delgi Studi, L'Aquila.
D'Aurizio
C
C
Marini
C
C
Prencipe
M
M
D000293:Adolescent; D000328:Adult; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy*; D010865:Pilot Projects; D012008:Recurrence
D003520:Cyclophosphamide